Protection of Ang1-7 through MKK/P38MAPKs inflammatory signal pathway on TNF- α stimulated mouse HL-1 cells

Xuwen Wang

Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University

Yuan Cao

Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University

Pradeep depark

Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University

Deepark Sharma

Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University

Guangping Li

Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University

Yanmin Xu (✉ xuyanminphdmd@sina.com)

Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University

Research Article

Keywords: Ang1-7, MKK/P38MAPKs, inflammatory signal pathway, HL-1 cells

Posted Date: November 17th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-1064422/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background

to explore the effect of Ang1-7 through MKK/P38MAPKs inflammatory signaling pathway on TNF- α -stimulated mouse HL-1 cells.

Methods

Using TNF- α (100 μ g/ml) to establish an inflammatory atrial fibrillation model in HL-1 cell, which derived from mouse atrial myocyte. treated HL-1 cells with different concentrations of Ang 1-7 (0.1, 1 and 10 mmol/L) and divided into 5 groups, namely A group(control group), B group(TNF), C group(TNF + Ang 1-7 0.1 mmol/L), D group(TNF + Ang 1-7 1 mmol/L) and E group(TNF + Ang 1-7 10 mmol/L). Firstly, different concentrations of Ang 1-7 (0.1 mmol/L, 1 mmol/L and 10 mmol/L) were used to stimulate for half an hour, and then TNF- α (100 μ g/ml) was added to stimulate for four hours. Both the cells and supernatant were collected. Cells were collected for Western Blotting to detect the protein expression of MKK3, MKK4, MKK6, PMMK4 and PP38. The supernatant was subjected to flow cytometry for detecting multi-inflammatory factors.

Results

Compared with the A group, the protein expression of MKK3, MKK4, MKK6, PMMK4 and PP38 was statistically significant increased after stimulation with inflammatory factors (TNF- α) ($P < 0.05$). After intervention with Ang 1-7, the protein expression of MKK3, MKK4, MKK6, PMMK4 and PP38 was statistically significant lower than that of B group ($P < 0.05$). There is no significant difference of the protein expression of P38 after stimulation with inflammatory factor (TNF- α). Compared with the A group, there was no significant difference in the protein expression of MAS after the stimulation of inflammatory factor (TNF- α). After the intervention of Ang 1-7, the protein expression of MAS was higher than that of the A group and B group, but there was no significant difference ($P > 0.05$). The expression of MAS protein had an increasing trend, but there was no significant difference ($P > 0.05$). TGF- β , TNF- α was significantly increased after stimulating factor (TNF- α) was given, but was decreased after the intervention of Ang 1-7, both there were statistically significant ($P < 0.05$). IL-6 also had the same trend, but there was no significant difference.

Conclusion

Ang1-7 through MKK/P38MAPKs inflammatory signal pathway protected on TNF- α stimulated mouse HL-1 cells

Introduction

Atrial fibrillation is the most common arrhythmia, its molecular mechanism is unclear. So far, the pathophysiology mechanisms of atrial fibrillation are not fully understood, the targeted therapy for atrial fibrillation fails to meet clinical needs. Many researches have clarified that atrial remodeling is a prerequisite for atrial fibrillation ⁽¹⁾. Other researches show that atrial fibrosis is not only related to the stimulation of cardiomyocytes and fibroblasts, but also related to the activation state of white blood cells. With the release of reactive oxygen species, cytokines and growth factors, white blood cells are recruited and subsequent increased matrix deposition, leading to unfavorable atrial remodeling ^(2,3). These inflammatory pathways are prerequisites for atrial fibrillation. The angiotensin- aldosterone - system is an important hormone system in the occurrence and development of atrial fibrillation. Therefore, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are becoming new drugs to prevent atrial fibrillation ⁽⁴⁾. Ang1-7 is produced by angiotensin-converting enzyme 2 (ACE2) catalyzed angiotensin I (Ang I) or angiotensin II (Ang II). The intracellular signal mechanism transmitted by MAS is still unclear. such as Akt phosphorylation, protein kinase C activation and mitogen-activated protein kinase (MAP) inhibition seem not be involved in this signal transduction pathway ⁽⁵⁾. Wang et al. also confirm that Ang1-7 attenuates the expression of heat shock protein (HSP27), thereby inhibiting the occurrence of atrial fibrillation ⁽⁶⁾. the Ang1-7/MAS conduction pathway should be further study and makes it an important target for the treatment of Atrial fibrillation .

1. Materials And Methods

1.1 Cell culture and groups divided

All cell experiments required ultraviolet rays to irradiate the operating table and the items needed for the experiment for 20 - 30 minutes before subsequent experiments carried out. HL-1 atrial myocytes were cultured in DMEM high glucose medium containing 10% fetal bovine serum or DMEM high glucose medium with penicillin/streptomycin (fetal bovine serum: penicillin/streptomycin: DMEM high glucose medium 10: 1.1: 100), in 5% CO₂ incubator at 37°C. Usually we used 12-well plates for Western Blotting and flow cytometry for detecting multi-inflammatory factors. Marked the blank control group as A group and A' group, experimental group TNF- α (TNF- α (100 μ g/ml)) as B group, B' group, TNF- α + Ang 1-7 (0.1 mm) as C group, C' Group, TNF- α + Ang 1-7(1 mm) as D group, D' group, TNF- α + Ang 1-7 (10 mm) as E group, E' group. Group A and Group A' were repeated controls for each other. The HL-1 cells were given different concentrations of Ang 1-7 (0.1 , 1 and 10 mmol/L) to stimulate for half an hour, and added TNF- α (100 μ g/ml) to stimulate for 4 h, in 5% CO₂ incubator at 37°C. After time was up, the cells and supernatant were collected, the cells were collected for Western Blotting, the supernatant was subjected to flow cytometry for detecting multi-inflammatory factors.

1.2 Western Blotting

Different treatments of HL-1 cells were used to extract protein from cell lysates using RAPI. Loaded 10 μ l protein samples and subjected to 10% SDS-polyacrylamide gel electrophoresis (140 MV) to separate proteins of different sizes and molecular weights. Transferred the protein to PVDF membrane, 200 MA, 1.5 h. PVDF membrane were blocked with Tris-buffered saline containing 10% nonfat milk at room temperature for 1 h, then incubated with the primary antibodies diluted in TBS at room temperature overnight. Primary antibodies used in this study were as followed: anti-P38MAPK antibody (#8690s, 1: 1000), anti-Phospho-p38mapk (Thr180/Tyr182) antibody (#4511, 1:1000), anti- β -actin antibody (1: 1000), anti-mkk3 antibody (1: 1000), anti-phospho-SEK1/mkk4 (C36C11, 1: 1000), Phospho-MKK4c36c11 (1: 1000), MKK6 (Cell signaling technology, 1: 1000) anti-MASsc-390453 (1: 500). Membranes were incubated with the secondary antibody at room temperature for 1 h and visualized using the chemiluminescence reagent ECL advance. TanonGis system was used to perform band gray scale analysis to calculate the net optical density, and the ratio of the net optical density of the target protein to the net optical density of β -actin represented the relative level of the target protein.

1.3 Flow cytometry

We chose 10 supernatant EP tubes (respectively con, TNF- α , TNF- α + Ang 1-7 (0.1 mm), TNF- α + Ang 1-7 (1 mm), TNF- α + Ang 1-7 (10 mm), repeated control for each group A and A'). Added beads mouse 10 μ l + Mouse Macrophage/Microglia Panel Detection Antibodies 10 μ l + legend plex Assay Buffer 20 μ l to each EP tube and mixed. Then added 10 μ l of supernatant to each EP tube and mixed, avoided light and shaken on a vortex shaker at a speed of 3 for 1.5 h. When the time was up, PE 10 μ l + legend plex Assay Buffer 10 μ l were added to each EP tube, and continued to avoid light and shaken on the vortex oscillator at a speed of 3 for 0.5 h. Taken a 15 ml centrifuge tube and added 14.5 ml deionized water (ddH₂O) + wash Buffer (20 $\times$) 750 μ l into it. After the shaking was over, added 500 μ l of the liquid in the prepared 15 ml centrifuge tube, and centrifuged of 600 rcf for 8 min at 4°C. After centrifugation, blue crystal precipitation could be seen. The upper layer of liquid was removed using a micropipette, leaving blue crystals. 200 μ l of the liquid was added in the prepared 15 ml centrifuge tube and subjected to the flow cytometry for multi-factor detection.

1.4 Statistical analysis

The results were compared with statistics using SPSS 25.0 software. Measurement data were expressed as mean $\pm$ standard deviation ($\bar{x} \pm s$). Significance test was performed using one-way analysis of variance (ANOVA), and LSD was used for comparison between groups when the test for homogeneity of variance was equal. When the homogeneity of variance is unequal, the comparison between the groups uses the Tamhneni method. $P < 0.05$ was considered statistically significant.

2. Results

2.1 Relative protein expression of MKK3/4/6 and PMMK4

Compared with the A group, the protein expressions of MKK3, MKK4, MKK6, and PMMK4 was significantly increased after stimulation with inflammatory factors (TNF- α), which was statistically significant ($P < 0.05$). After intervention with Ang 1-7, the protein expression of MKK3, MKK4, MKK6, and PMMK4 was significantly lower than that of the stimulation group ($P < 0.05$). The protein expressions of MKK4, MKK6 and PMMK4 between groups B, C, and D, E showed an increasing trend, but there was no significant difference ($P > 0.05$). There is no significant difference in multiple comparisons of MKK3, MKK4, MKK6, PMMK4 between groups B, C, and D,E ($P > 0.05$) (Table 1 and Fig. 1).

Table 1

Comparison of MKK3, MKK4, MKK6, PMMK4 protein expression in HL-I cells of each group(x $\pm$ s)

Group	n	MKK3	MKK4	MKK6	Pmkk4
A Group(Control)	6	1.06 $\pm$ 0.217*	0.78 $\pm$ 0.215*	0.92 $\pm$ 0.091*	0.66 $\pm$ 0.165*
B Group(TNF- α)	6	1.49 $\pm$ 0.323	1.20 $\pm$ 0.139	1.22 $\pm$ 0.089	1.11 $\pm$ 0.126
C Group(TNF- α + Ang 1-7 0.1mm)	6	0.92 $\pm$ 0.262*	0.61 $\pm$ 0.199*	0.81 $\pm$ 0.158*	0.85 $\pm$ 0.119*
D Group(TNF- α + Ang 1-7 1 mm)	6	0.96 $\pm$ 0.164*	0.62 $\pm$ 0.171*	0.66 $\pm$ 0.246*	0.74 $\pm$ 0.181*
E Group(TNF- α + Ang 1-7 10 mm)	6	0.99 $\pm$ 0.170*	0.58 $\pm$ 0.216*	0.64 $\pm$ 0.183*	0.65 $\pm$ 0.250*
*: Compared with TNF- α group, $P < 0.05$					

2.2 Relative Protein Expression Of P38mapk And Pp38mapk

Compared with A group, there was no significant difference in P38 protein expression after inflammatory factor (TNF- α) stimulation, but PP38 protein expression was significantly increased ($P < 0.05$). After the intervention of Ang 1-7, the protein expression of PP38 was significantly lower than that of A group ($P < 0.05$), but there was no significant difference in the reduction of the protein in group B. There was no significant difference in the protein expression of P38. The expression of PP38 protein in groups B, C, and D, E had a decreasing trend, but there was no significant difference ($P > 0.05$). There was significant differences of the protein expression of PP38 within multiple comparisons between group A and groups C and D ($P < 0.05$), and there was significant differences between group B and group D ($P < 0.05$). There was no significant difference of the protein expression of PP38 between group B and groups A and C (Table 2 and Fig. 2).

Table 2
Comparison of P38 and PP38 protein expression in HL-I cells of each group($\bar{x}\pm s$)

Group	n	P38	PP38
A group (Control)	6	1.40±0.654	1.09±0.399*
B group (TNF- α)	6	1.53±0.704	1.53±0.525
C group (TNF- α + Ang 1-7 0.1mm)	6	1.35±0.509	1.13±0.254
D group (TNF- α + Ang 1-7 1 mm)	6	1.33±0.387	0.82±0.323*
E group (TNF- α + Ang 1-7 10 mm)	6	1.29±0.364	0.55±0.287*
*: Compared with TNF- α group, $P < 0.05$			

2.3 Expression Of Mas Receptor

Compared with A group, there was no significant difference in the protein expression of MAS after stimulation with inflammatory factor (TNF- α). After intervention with Ang 1-7, the protein expression of MAS was higher than that of B group and C group, but there was no significant difference ($P > 0.05$). The expression of MAS protein in groups C, D, and E showed an increasing trend, but there was no significant difference ($P > 0.05$). There was no significant difference of MAS protein expression in multiple comparisons within the groups ($P > 0.05$) (Table 3 and Fig. 3).

Table 3
Comparison of MAS protein expression in HL-I cells of each group($\bar{x}\pm s$)

Group	n	MAS
A group (Control)	6	1.72±0.985
B group (TNF- α)	6	1.78±0.977
C group (TNF- α + Ang 1-7 0.1mm)	6	2.10±0.928
D group (TNF- α + Ang 1-7 1 mm)	6	2.29±0.996
E group (TNF- α + Ang 1-7 10 mm)	6	2.54±1.007
*: Compared with TNF- α group, $P < 0.05$		

2.4 Flow multi-factor detection of the expression of inflammatory factors of TGF-β, IL-6, TNF-α

Compared with the A group, the TGF-β of group B was significantly increased after stimulating factor (TNF-α) was given, and it was statistically significant ($P < 0.05$). The expression of TGF-β was decreased after the intervention of Ang 1-7, and there was a significant difference in group E ($P < 0.05$). There is no significant difference between group C, D and group B ($P > 0.05$). There is no significant difference in multiple comparisons within the group between C,D and E($P > 0.05$) (Table 4 and Fig. 4). Compared with A group, IL-6 in group B increased after stimulating factor (TNF-α) was given. The expression of TGF-β decreased after the intervention of Ang 1-7,($P > 0.05$) (Table 4 and Fig. 4). Compared with the A group, TNF-α in group B was significantly increased after stimulating factor (TNF-α) was given, and it was statistically significant ($P < 0.05$). The expression of TNF-α was significantly decreased after the intervention of Ang 1-7, and it was statistically significant ($P < 0.05$). However, there was no significant difference in multiple comparisons between groups C, D and E ($P > 0.05$) (Table 4 and Fig. 4).

Table 4 Comparison of TGF-βIL6TNF-α protein expression in HL-I cells of each group(x±s)				
Group	n	TGF-β	IL-6	TNF-α
A group (Control)	6	1.00±0.00*	1.00±0.00	1.00±0.00*
B group (TNF-α)	6	1.47±0.204	5.96±3.961	21.12±4.907
C group (TNF-α + Ang 1-7 0.1mm)	6	1.30±0.092	3.65±1.633	8.64±0.747*
D group (TNF-α + Ang 1-7 1 mm)	6	1.09±0.156	2.76±1.656	6.07±0.404*
E group (TNF-α + Ang 1-7 10 mm)	6	1.19±0.216*	3.19±1.407	7.66±1.554*
*: Compared with TNF-α group, $P < 0.05$				

3. Discussion

P38 kinase is a proline-mediated serine/threonine kinase of the mitogen-activated protein kinase (MAPK) family, which is activated by environmental stress and signal pathways. P38MAPKs (especially P38-α) are involved in cellular responses to stress, environmental and intracellular stresses at many levels, such as high osmotic pressure, oxidative stress, inflammation, DNA damage and other physiological conditions that involve cell changes ⁽⁷⁾. P38 -α is involved in a variety of functions, and the disorder of this pathway is related to diseases such as inflammation, immune disorders or cancer ⁽⁸⁾. The activation of P38 is mediated by the phosphorylation of specific regulatory tyrosine and threonine sites, and the three kinases MKK3, MKK4, and MKK6 are the upstream activators of P38⁽⁹⁾. P38α regulates many functions of cardiomyocytes, including hypertrophy, contractility, fibrosis and apoptosis ^(10,11,12).

Atrial muscle fibrosis leads to local conduction slowdown and conduction disorders, leading to unidirectional conduction block⁽¹³⁾. Fibrosis increases the number of fibroblasts and change their characteristics, by changing the interaction between cardiomyocytes and fibroblasts to couple the electrophysiological behavior of cardiomyocytes, thereby promoting atrial fibrillation⁽¹⁴⁾. The role of the RAAS system in the remodeling of atrial structure has been confirmed. Clinical studies have shown that RAAS inhibitors are benefit for patients with atrial fibrillation after pulmonary vein isolation⁽¹⁵⁾. RAAS inhibitors also inhibit atrial fibrosis and atrial remodeling, and delay atrial fibrillation^(16,17). Ang II is the central factor of RAAS, which causes vasoconstriction, increases myocardial afterload, promotes left ventricular hypertrophy, indirectly increases atrial pressure, and increases the ductility of myocardial cells⁽¹⁸⁾. In addition, Ang II increases oxidative stress, thereby inducing inflammatory collagen fiber deposition and causing atrial fibrosis. In animals with an overexpression of angiotensin converting enzyme, Ang II levels are significantly increased, and there was obvious atrial enlargement, atrial fibrosis and atrial fibrillation. Ang II promotes atrial remodeling through TGF- β /Smad2/3 signaling pathway⁽¹⁹⁾. MAPKs are a group of important downstream molecules of Ang II, which are involved in the increased expression of TGF- β 1 inducing by Ang II⁽²⁰⁾. The increased expression of TGF- β 1 inducing by Ang II is the main mechanism of Ang II inducing atrial fibrosis. In a clinical study, 56 patients with rheumatic heart disease are divided into atrial fibrillation group and sinus rhythm group. Left atrial appendage tissue is collected during cardiac surgery to assess myocardial fibrosis. The study found that the atrial MAPKs activity in the atrial fibrillation group is significantly higher than sinus rhythm group, the atrial TGF- β 1 and CTGF mRNA and protein expression in patients with atrial fibrillation increases significantly, confirming that the MAPKs/TGF- β 1/TRAF6 signaling pathway is involved in the occurrence of atrial fibrosis in patients with atrial fibrillation⁽²¹⁻²²⁾. In addition, the increased expression of TGF- β 1 induced by Ang II is the main mechanism of Ang II-induced myocardial fibrosis⁽²³⁾. Ang II increased the activation of mouse fibroblast MAPKs, up-regulate the expression of TGF- β 1 and CTGF, and promote the proliferation of fibroblasts⁽²⁴⁾. The increase in CTGF expression induced by Ang II or TGF- β 1 is an important factor involved in atrial fibrosis and atrial fibrillation. In vitro studies on mouse fibroblasts show that Ang II stimulates TGF- β 1 on atrial fibroblasts, which acts in a Smad-independent manner. In this study, it is also confirmed that the TGF- β 1/TRAF6 signaling pathway is involved in atrial fibrosis.

Transforming growth factor (TGF- β 1) is a key fibroblast growth factor. TGF- β 1 regulates cell proliferation, apoptosis and migration, and regulate the synthesis of extracellular matrix (such as up-regulating the expression of fibronectin and collagen fibers). Overexpression of TGF- β 1 may cause atrial fibrosis and atrial fibrillation. The increase in CTGF expression induced by Ang II or TGF- β is an important factor involved in atrial fibrosis and atrial fibrillation⁽²⁵⁾. TGF- β may be the main switch that regulates the transition from inflammatory response to fibrosis⁽²⁶⁾. Masaki Ikeuchi et al. show that early inhibition of TGF- β aggravates ventricular dysfunction and inflammatory response, while late destruction of TGF- β signaling protects interstitial fibrosis and hypertrophic remodeling⁽²⁷⁾. Peter P R et al. show that although extensive inhibition of TGF- β after infarction lead to early death of heart rupture, the specific destruction of TGF- β receptors by cardiomyocytes has a protective effect and extensively stimulates anti-

inflammatory and cytoprotective signals⁽²⁸⁾. Therefore, the adverse effects of early TGF- β inhibition on infarcted myocardium may not be due to the direct effect of cardiomyocyte survival, but reflect the loss of anti-inflammatory effects of inflammatory cells, endothelial cells or fibroblasts⁽²⁹⁾.

This study confirmed that inflammatory stress triggers the MKK-P38MAPKs signaling pathway, which increased the expression of MKK3, MKK4, MKK6, and PMKK4 proteins, and the expression of phosphorylated PP38 protein was also significantly increased, and the concentration of inflammatory factors TGF β also increased. Thus, these changes may cause myocardial fibrosis leading to the occurrence and maintenance of atrial fibrillation.

When a large number of myocardial cells are suddenly damaged after myocardial infarction, resulting in the formation of collagen scars⁽³⁰⁾. Necrotic cells released dangerous signals, which activate innate immune pathways, and trigger a strong inflammatory response. Downstream signals focus on the activation of mitogen-activated protease (MAPK) and NF- κ B. These pathways drive the expression of pro-inflammatory genes including inflammatory factors (such as TNF- α , IL-1 β , IL-6 and IL-18)^(31–33). Inflammation signals promote the adhesion between leukocytes and endothelial cells, leading to extravasation of neutrophils and monocytes. When the infiltrating white blood cells clear the necrotic cells, mediators that inhibit inflammation are released^(34, 35). The inhibition of inflammatory response is related to the activation of repair cells, leading to the proliferation of fibroblasts to maintain the integrity of the infarcted ventricle^(36–38). TNF- α is an important factor in vascular inflammation, and its level is elevated in vascular diseases. Many effects of TNF- α are similar to Ang II. Arenas et al. report that Ang II regulates endothelial cells secreting inflammatory cytokines TNF- α and matrix metalloproteinase-2 (MMP)⁽³⁹⁾. Ang II stimulates the production of TNF- α through a PKC-dependent pathway in macrophages⁽⁴⁰⁾. In monocytes, macrophages, vascular smooth muscle cells and endothelial cells, TNF- α activates NF- κ B, thereby inducing the production of adhesion molecules and chemokines, such as IL-6 and IL-8⁽⁴¹⁾. Cytokines also play an important role in the occurrence and development of atherosclerotic lesions⁽⁴²⁾. The level of IL-18 expressed in atherosclerotic lesions is elevated. Sahar et al. prove that IL-18 activates Src, PKC, and MAPK. In Ang II stimulated smooth muscle cells, IL-18 is enhanced by activating NF- κ B, and Ang II also induces IL-18 receptor mRNA expression through STAT3⁽⁴³⁾. Nami K et al. use Ang II to stimulate the HL-1 cell line. Ang II induces reactive oxygen species (ROS) production and activates MAPK, TGF- β 1, IL-6, IL-1 β , NF- κ B, and TNF- α . Ang II regulates atrial fibrillation through inflammatory mechanisms and MAPK signaling pathways produced ROS^(44, 45). In addition, TNF- α , IL-6, and IL-1 β are also the prototype stress activators of P38- α . Cytokines bind to different types of surface receptors to determine the p38- α phosphorylation pathway, usually with TRAF ubiquitin ligase and TAK1 and others with MAPK3. The P38- α -MK2 pathway regulates the expression of TNF- α and mediated the production of TNF- α induced pro-inflammatory factors, while limits TNF- α induced apoptosis.

This study confirmed that the administration of inflammatory stimuli (TNF- α) has an effect through the MKK-P38-MAPKs signaling pathway. The expression of inflammatory factors was as follows: TGF- β and

TNF- α were significantly increased and statistically significant, and IL-6 level was also increased, but there was no significant difference.

The formation and degradation mechanism of angiotensin II (Ang II) is an important factor that determines its ultimate physiological effect. Ang II is an octapeptide. Angiotensin is cut into angiotensin I by aspartase renin, and angiotensin I is converted into Ang II by angiotensin-converting enzyme (ACE) ⁽⁴⁶⁾. A recently study discovers carboxypeptidase ACE2 cleaves an amino acid from Ang I or Ang II, reduces the level of Ang II and increases the vasodilatory metabolite Ang ₁₋₇ ⁽⁴⁷⁾. ACE2/Ang₁₋₇/MAS axis regulation regulates fiber generation and remodeling. In another study, male rats are divided into sham operation group, Ang II group, Ang II + Ang ₁₋₇ group, Ang II + Ang ₁₋₇ + A₇₇ group, stimulate for 4 weeks, and finally tissues are collected. Results indicate that chronic Ang ₁₋₇ prevents cardiomyocyte hypertrophy and interstitial fibrosis induced by hypertension. Ang ₁₋₇ acts directly on the heart tissue. It is also confirmed that the anti-fibrosis and anti-hypertrophy effects of Ang ₁₋₇ are not mediated by changes in the number of AT1 or AT2 cardiac receptors ⁽⁴⁸⁾. In a mouse model of asthma, it is also confirmed that Ang ₁₋₇ inhibits ovalbumin-induced airway leukocyte influx, perivascular and peribronchial inflammation, fibrosis, and goblet cell hyperplasia or metaplasia ⁽⁴⁹⁾. The ACE2/Ang₁₋₇/MAS axis regulates the recruitment and activation of leukocytes. In the model of pulmonary hypertension, the activation of the ACE2/Ang₁₋₇/MAS axis also regulates the expression of pro-inflammatory factors, reducing the expression of TNF- α , TGF- β , IL-6, IL-1 β and increases the expression of anti-inflammatory factor IL-10 ^(50, 51). Jun Mori implants micro-osmotic pumps in male db/db mice (diabetic cardiomyopathy mice) at the age of 5 months, and gives them Ang ₁₋₇ for 28 days. It is found that Ang ₁₋₇ inhibits the increase of myocardial protein kinase C level and the loss of extracellular signal-regulated kinase 1/2 phosphorylation, and reduces the levels of triglyceride and ceramide in the heart of db/db mice, and increases the expression of triglyceride lipase in myocardial fat ⁽⁵²⁾.

In this study, the protein expressions of MKK3, MKK4, MKK6, PMMK4, and PP38 were significantly increased after inflammatory factor (TNF- α) stimulation, and after intervention with Ang ₁₋₇, the protein expression of MKK3, MKK4, MKK6, PMMK4, and PP38 was significantly lower than the stimulation group ($P < 0.05$). In terms of inflammatory factors, TGF- β and TNF- α were significantly increased after TNF- α stimulation, and the expression of TGF- β and TNF- α was significantly reduced after Ang ₁₋₇ intervention ($P < 0.05$). IL-6 also had the same effects as TGF- β and TNF- α trend, but there was no statistically significant.

Conclusions

Ang1-7 through MKK/P38MAPKs inflammatory signal pathway protected on TNF- α stimulated mouse HL-1 cells

Declarations

Funding: no fund supported

Conflicting Interests:

All authors declare that have no financial or non-financial competing interests in relation to our work. Such as 1 .Receiving reimbursements, fees, funding, or salary from an organization that may in any way gain or lose financially from the publication of the manuscript, either now or in the future.2 .Holding stocks or shares in an organization that may in any way gain or lose financially from the publication of the manuscript, either now or in the future.3 .Holding, or currently applying for, patents relating to the content of the manuscript.4 .Receiving reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript.

All authors declare that we have no any political, personal, religious, ideological, academic, and intellectual competing interests in relation to our work.

All authors declare that we have no Authors from pharmaceutical companies, or other commercial organizations

All authors declare that we have no Editorial Board Members and Editors in relation to our work.

Ethics approval :Appropriated approvals

Acknowledgements: none

References

1. K. Newton,V. M. Dixit. "Signaling in innate immunity and inflammation," (in eng), *Cold Spring Harb Perspect Biol*, 2012,4(3):1-3. doi: 10.1101/cshperspect.a006049.
2. Y. Kobayashi. "Neutrophil infiltration and chemokines," (in eng), *Crit Rev Immunol*. 2006,26(4):307–16. doi: 10.1615/critrevimmunol.v26.i4.20.
3. G. E. White, A. J. Iqbal, D. R. Greaves. "CC chemokine receptors and chronic inflammation–therapeutic opportunities and pharmacological challenges," (in eng), *Pharmacol Rev*. 2013,65(1):47–89. doi: 10.1124/pr.111.005074.
4. Y. Sun, K. T. Weber. "Angiotensin converting enzyme and myofibroblasts during tissue repair in the rat heart," (in eng), *J Mol Cell Cardiol*.1996,28(5):851–8.doi: 10.1006/jmcc.1996.0080.
5. Z. Su, J. Zimpelmann, K. D. Burns. "Angiotensin-(1-7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells," (in eng), *Kidney Int*.2006,69(12):2212–8. doi: 10.1038/sj.ki.5001509.
6. X. Wang, Shangguan, and G. Li. "Angiotensin-(1-7) prevents atrial tachycardia induced-heat shock protein 27 expression," (in eng), *J Electrocardiol*. 2018,51(1):117–120. doi: 10.1016/j.jelectrocard.2017.08.015.

7. B. Canovas, A. R. Nebreda, "Diversity and versatility of p38 kinase signalling in health and disease," (in eng), *Nat Rev Mol Cell Biol*.2021, 27:1–21.doi: 10.1038/s41580-020-00322-w
8. Y. J. Kang, A. Seit-Nebi, R. J. Davis, and J. Han, "Multiple activation mechanisms of p38alpha mitogen-activated protein kinase," (in eng), *J Biol Chem*.2006,281(36):26225–34. doi: 10.1074/jbc.M606800200.
9. G. Remy."Differential activation of p38MAPK isoforms by MKK6 and MKK3," (in eng), *Cell Signal*, 2010, 22(4):660–7.doi: 10.1016/j.cellsig.2009.11.020.
10. G. Sabio, R. J. Davis. "TNF and MAP kinase signalling pathways," (in eng), *Semin Immunol*. 2014,26(3):237–45. doi: 10.1016/j.smim.2014.02.009.
11. D. Brancho. "Mechanism of p38 MAP kinase activation in vivo," (in eng), *Genes Dev*. 2003,17(16):1969-78. doi: 10.1101/gad.1107303.
12. M. B. Menon. "p38(MAPK)/MK2-dependent phosphorylation controls cytotoxic RIPK1 signalling in inflammation and infection," (in eng), *Nat Cell Biol*, vol. 19, no. 10, pp. 1248–1259, Oct 2017, doi: 10.1038/ncb3614.
13. D. Li, S. Fareh, T. K. Leung, and S. Nattel, "Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort," (in eng), *Circulation*, 1999, 100(1):87–95.doi: 10.1161/01.cir.100.1.87.
14. L. Yue, J. Xie, and S. Nattel. "Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation," (in eng), *Cardiovasc Res*, 2011,89(4):744–53. doi: 10.1093/cvr/cvq329.
15. R. Weerasooriya. "Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up?," (in eng), *J Am Coll Cardiol*. 2011,57(2):160-6.doi: 10.1016/j.jacc.2010.05.061.
16. H. Nakashima, K. Kumagai. "Reverse-remodeling effects of angiotensin II type 1 receptor blocker in a canine atrial fibrillation model," (in eng), *Circ J*. 2007,71(12):1977–82. doi: 10.1253/circj.71.1977.
17. G. Huang. "Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers decrease the incidence of atrial fibrillation: a meta-analysis," (in eng), *Eur J Clin Invest*. 2011,41(7):719–33. doi: 10.1111/j.1365-2362.2010.02460
18. H. D. Xiao. "Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death," (in eng), *Am J Pathol*. 2004, 165(3):1019–32.doi: 10.1016/s0002-9440(10)63363-9.
19. X. He. "Atrial fibrillation induces myocardial fibrosis through angiotensin II type 1 receptor-specific Arkadia-mediated downregulation of Smad7," (in eng), *Circ Res*. 2011,108(2):164–75. doi: 10.1161/circresaha.110.234369.
20. T. Naito, T. Masaki, D. J. Nikolic-Paterson, et al. "Angiotensin II induces thrombospondin-1 production in human mesangial cells via p38 MAPK and JNK: a mechanism for activation of latent TGF-beta1," (in eng), *Am J Physiol Renal Physiol*. 2004,286(2):278–87. doi: 10.1152/ajprenal.00139.2003.
21. D. Zhang. "Role of the MAPKs/TGF-β1/TRAF6 signaling pathway in atrial fibrosis of patients with chronic atrial fibrillation and rheumatic mitral valve disease," (in eng), *Cardiology*. 2014,129(4):216–23. doi: 10.1159/000366096.

22. J. Gu. "Angiotensin II increases CTGF expression via MAPKs/TGF- β 1/TRAF6 pathway in atrial fibroblasts," (in eng), *Exp Cell Res*. 2012,318(16):2105–15. doi: 10.1016/j.yexcr.2012.06.015.
23. K. J. Loniewski, S. Patial, and N. Parameswaran, "Sensitivity of TLR4- and -7-induced NF kappa B1 p105-TPL2-ERK pathway to TNF-receptor-associated-factor-6 revealed by RNAi in mouse macrophages," (in eng), *Mol Immunol*. 2007, 44(15):3715–23. doi: 10.1016/j.molimm.2007.04.002.
24. R. Khan, R. Sheppard, "Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia," (in eng), *Immunology*. 2006,118(1):10–24. doi: 10.1111/j.1365-2567.2006.02336.x.
25. W. C. Ko. "Elevated expression of connective tissue growth factor in human atrial fibrillation and angiotensin II-treated cardiomyocytes," (in eng), *Circ J*. 2011,75(7):1592–600. doi: 10.1253/circj.cj-10-0892.
26. M. Dobaczewski. "Smad3 signaling critically regulates fibroblast phenotype and function in healing myocardial infarction," (in eng), *Circ Res*. 2010,107(3):418–28. doi: 10.1161/circresaha.109.216101.
27. M. Dobaczewski, W. Chen, and N. G. Frangogiannis, "Transforming growth factor (TGF)- β signaling in cardiac remodeling," (in eng), *J Mol Cell Cardiol*. 2011,51(3):600–6. doi: 10.1016/j.yjmcc.2010.10.033.
28. M. Ikeuchi. "Inhibition of TGF-beta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction," (in eng), *Cardiovasc Res*. 2004,64(3):526–35. doi: 10.1016/j.cardiores.2004.07.017.
29. P. P. Rainer. "Cardiomyocyte-specific transforming growth factor β suppression blocks neutrophil infiltration, augments multiple cytoprotective cascades, and reduces early mortality after myocardial infarction," (in eng), *Circ Res*. 2014, 114(8):1246–57. doi: 10.1161/circresaha.114.302653.
30. S. D. Prabhu, N. G. Frangogiannis, "The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis," (in eng), *Circ Res*. 2016,119(1):91–112. doi: 10.1161/circresaha.116.303577.
31. N. Voigt. "Cellular and molecular mechanisms of atrial arrhythmogenesis in patients with paroxysmal atrial fibrillation," (in eng), *Circulation*. 2014,129(2):145–56. doi: 10.1161/circulationaha.113.006641.
32. E. Patterson, S. S. Po, B. J. Scherlag, et al. "Triggered firing in pulmonary veins initiated by in vitro autonomic nerve stimulation," (in eng), *Heart Rhythm*. 2005,2(6):624–31. doi: 10.1016/j.hrthm.2005.02.012.
33. S. Nattel, D. Dobrev, "The multidimensional role of calcium in atrial fibrillation pathophysiology: mechanistic insights and therapeutic opportunities," (in eng), *Eur Heart J*. 2012,33(15):1870–7. doi: 10.1093/eurheartj/ehs079.
34. D. Rohde. "S100A1 is released from ischemic cardiomyocytes and signals myocardial damage via Toll-like receptor 4," (in eng), *EMBO Mol Med*. 2014,6(6):778–94. doi:10.15252/emmm.201303498.
35. I. M. Seropian. "Galectin-1 controls cardiac inflammation and ventricular remodeling during acute myocardial infarction," (in eng), *Am J Pathol*, 2013,182(1):29–40. doi:10.1016/j.ajpath.2012.09.022.

36. C. A. Souders, S. L. Bowers, and T. A. Baudino, "Cardiac fibroblast: the renaissance cell," (in eng), *Circ Res.* 2009,105(12):1164–76. doi: 10.1161/circresaha.109.209809.
37. A. V. Shinde, N. G. Frangogiannis, "Fibroblasts in myocardial infarction: a role in inflammation and repair," (in eng), *J Mol Cell Cardiol.* 2014,70(70):74–82. doi: 10.1016/j.yjmcc.2013.11.015.
38. A. Saxena. "IL-1 induces proinflammatory leukocyte infiltration and regulates fibroblast phenotype in the infarcted myocardium," (in eng), *J Immunol.* 2013,191(9):4838–48. doi: 10.4049/jimmunol.1300725.
39. I. A. Arenas, Y. Xu, P. Lopez-Jaramillo, S. T. Davidge, "Angiotensin II-induced MMP-2 release from endothelial cells is mediated by TNF-alpha," (in eng), *Am J Physiol Cell Physiol.* 2004,286(4):779–84. doi: 10.1152/ajpcell.00398.2003.
40. D. Kalra, N. Sivasubramanian, D. L. Mann, "Angiotensin II induces tumor necrosis factor biosynthesis in the adult mammalian heart through a protein kinase C-dependent pathway," *Circulation*,2002,105(18):2198–205.doi: 10.1161/01.cir.0000015603.84788.47.
41. B. Schieffer. "Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability," (in eng), *Circulation.* 2000,101(12):1372–8. doi: 10.1161/01.cir.101.12.1372.
42. N. Gerdes, G. K. Sukhova, P. Libby, R. S. Reynolds. "Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis," (in eng), *J Exp Med.* 2002,195(2):245–57. doi: 10.1084/jem.20011022.
43. S. Sahar, R. S. Dwarakanath, M. A. Reddy, L. Lanting, I. Todorov"Angiotensin II. enhances interleukin-18 mediated inflammatory gene expression in vascular smooth muscle cells: a novel cross-talk in the pathogenesis of atherosclerosis," (in eng), *Circ Res.* 2005,96(10):1064–71. doi: 10.1161/01.RES.0000168210.10358.f4.
44. J. Gu. "Beneficial effects of pioglitazone on atrial structural and electrical remodeling in vitro cellular models," (in eng), *J Mol Cell Cardiol.* 2013,65(1):1–8. doi: 10.1016/j.yjmcc.2013.09.016.
45. N. Kim. "Angiotensin II affects inflammation mechanisms via AMPK-related signalling pathways in HL-1 atrial myocytes," (in eng), *Sci Rep.* 2017,7(1):10328–36. doi: 10.1038/s41598-017-09675-3.
46. M. A. Crackower. "Angiotensin-converting enzyme 2 is an essential regulator of heart function," (in eng). *Nature*,2002,417(68):822–8. doi: 10.1038/nature00786.
47. U. Danilczyk, J. M. Penninger, "Angiotensin-converting enzyme II in the heart and the kidney". *Circ Res.* 2006,98(4):463–71. doi: 10.1161/01.RES.0000205761.22353.5f.
48. J. L. Grobe. "Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7)," (in eng), *Am J Physiol Heart Circ Physiol.* 2007,292(2):736–42. doi: 10.1152/ajpheart.00937.2006.
49. A. Z. El-Hashim, W. M. Renno, R. Raghupathy, H. T. Abduo, S. Akhtar."Angiotensin-(1-7) inhibits allergic inflammation, via the MAS1 receptor, through suppression of ERK1/2- and NF-κB-dependent pathways," (in eng), *Br J Pharmacol.* 2012,166(6):1964–76. doi: 10.1111/j.1476-5381.2012.01905.x.

50. Y. Yamazato. "Prevention of pulmonary hypertension by Angiotensin-converting enzyme 2 gene transfer," *Hypertension*, 2009, 54(2):365–71. doi: 10.1161/hypertensionaha.108.125468.
51. A. C. Simões, Silva, K. D. Silveira, A. J. Ferreira, and M. M. Teixeira, "ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis," (in eng), *Br J Pharmacol*. 2013, 169(3):477–92. doi: 10.1111/bph.12159.
52. J. Mori. "Angiotensin 1-7 ameliorates diabetic cardiomyopathy and diastolic dysfunction in db/db mice by reducing lipotoxicity and inflammation," (in eng), *Circ Heart Fail*. 2014, 7(2):327-39. doi: 10.1161/circheartfailure.113.000672.

Figures

Figure 1

Relative protein expression of MKK3, MKK4, MKK6 and PMKK4 CON: blank control group, group A: TNF- α treated, group B: TNF- α + Ang 1-7 0.1 mm, group C: TNF- α + Ang 1-7 1 mm, group D: TNF- α + Ang 1-7 10 mm. *: Compared with group A (TNF- α treated), the indicated protein expression has a statistically significant, $P < 0.05$.

Figure 2

Relative protein expression of P38 and PP38 Con: blank control group, group A: TNF- α treated, group B: TNF- α + Ang 1-7 0.1 mm, group C: TNF- α + Ang 1-7 1 mm, group D: TNF- α + Ang 1-7 10 mm. *: Compared with group A (TNF- α treated), the indicated protein expression has a statistically significant, $P < 0.05$.

Figure 3

Relative protein expression of MAS CON: blank control group, group A: TNF- α treated, group B: TNF- α + Ang 1-7 0.1 mm, group C: TNF- α + Ang 1-7 1 mm, group D: TNF- α + Ang 1-7 10 mm. *: Compared with

group A (TNF-α treated), the indicated protein expression has a statistically significant, $P < 0.05$.

Figure 4

Relative protein expression of TGF-β and IL-6. Con: blank control group, group A: TNF-α treated, group B: TNF-α + Ang 1-7 0.1 μg/ml, group C: TNF-α + Ang 1-7 1 μg/ml, group D: TNF-α + Ang 1-7 10 μg/ml. *: Compared with group A (TNF-α treated), the indicated protein expression has a statistically significant, $P < 0.05$.